Disappointment as phase 3 trials for Alzheimer's drug ganteneurumab show no clinical benefit
In a press release today, pharmaceutical company Roche announced results from its phase 3 trials of immunotherapy drug ganteneurumab. The results show that the drug failed to slow cognitive decline in people with early-stage Alzheimer's disease.